American Journal of BioMedicine
Volume 11, Issue 3, 2023, Pages 110-123 | http://dx.doi.org/10.18081/2333-5106/2023.11/110
Nasser Ghaly Yousif *1, Fadhil G. Al-Amran 2
Received 15 February 2023; Revised 11 May 2023; Accepted 16 June 2023; Published 30 July 2023
Allogeneic hematopoietic stem cell transplantation is a well-proven treatment for hematologic malignancies and non-malignancies, but it has a high risk of disease recurrence and severe transplant-related morbidity and death. The mortality and long-term survival of post-allogeneic hematopoietic stem cell transplant patients are improving due to improvements in condition procedures, methods, novel medicines, and supportive care practices. Allogeneic hematopoietic stem cell transplant (allo-HCT) findings, nonetheless, still present a chance for recovery. The results of this investigation updated previous research on risk factors for death following allogeneic HCT. We performed a systematic review and meta-analysis to assess mortality post allo-HCT through a comprehensive literature search using PUBMED/MEDLINE, CINAHL, Web of Science, and EMBASE up to April 30, 2023 and extracted clinical outcome data relating to benefits followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search identified 551 studies. Only 12 studies (n = 450 patients) met our inclusion criteria. OS rates were the subject of the meta-analysis. The following were the outcomes of heterogeneity tests: According to Chi2=9.14, df=6, P=0.17, and I2=34 percent, the study's data did not appear to be heterogeneous. The OS rate did not differ significantly (P>0.05) using the fixed-effect model analysis. In conclusion, the HSCT must offer the best overall survival, quality of life, and cost outcomes compared to any other treatment strategy. More studies will need a lot of data, and careful data analysis will help get clear data on HSCT outcomes.
Keywords: SPRISMA; Post allo-HCT; PUBMED/MEDLINE; HSCT
Copyright © 2023 Yousif NG, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|1. Ozdemir ZN, Civriz Bozdağ S. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci 2018; 57:163-167.
|2. Zhang W, Zhou R, Ma L, Wang Z, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119:296-307.
|3. Lee SE, Cho BS, Kim JH, et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant 2013; 48:587-592.
|4. Xue S, Liu F, Zhang Y, Tan Y, Wang J. Clinical study of cord blood mesenchymal stem cells combined with Eltrombopag when treating graft dysfunction after allogeneic hematopoietic stem cell transplantation. Int J Blood Transfus Hematol 2022; 45:132-139.|
|5. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13:1461-8.
|6. Gao J, Zhang Y, Su L. Advances in prevention of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Chinese Journal of Medical Frontiers 2022; 14:53-58.|
|7. Pasquini MC, Wang Z, Horowitz MM, Gale RP. Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010; 2010:87-105.|
|8. Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11:331-8.
|9. Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukemia to stem cells Nature 2017; 547:104-08.
|10. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264-78.
|11. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127: 62-70.
|12. Bhatia S, Dai C, Landier W, Hageman L, Wu J, Schlichting E et al. Trends in Late Mortality and Life Expectancy after Allogeneic Blood or Marrow Transplantation over 4 Decades: A Blood or Marrow Transplant Survivor Study Report. JAMA Oncology 2021; 7(11):1626-1634.
|13. Godara A, Nauman S, Holtzman N, et al. Factors Associated with Early Mortality in Patients Undergoing Allogeneic Stem Cell Transplantation.|
|14. Francisco L, Armenian SH, Arora M, et al. Progressive decline in late mortality after hematopoietic cell transplantation (HCT) over 40 years-a report from BMTSS [abstract]. Blood 2016; 128(22):691.
|15. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29(16):2230-2239.
|16. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28(6):1011-1016.
|17. Holmqvist AS, Chen Y, Wu J, et al. Assessment of late mortality risk after allogeneic blood or marrow transplantation performed in childhood. JAMA Oncol 2018; 4(12):e182453.
|18. Vajdic CM, Mayson E, Dodds AJ, et al. CAST study investigators. Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study. Biol Blood Marrow Transplant 2016; 22(5):949-56.
|19. Gooley TA, Chien JW, Pergam SA. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med. 2010; 363(22): 2091-2101.
|20. Schechter T, Pole JD, Darmawikarta D, Doyle J, et al. Late mortality after hematopoietic SCT for a childhood malignancy. Bone Marrow Transplant 2013; 48(10):1291-5.
|21. Pond GR, Lipton JH, Messner HA. Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transplant 2006; 12(4):422-9.
|22. Arora M, Sun CL, Ness KK, et al. Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study. JAMA Oncol 2016; 2(10):1277-1286.
|23. Shankar SM, Carter A, Sun CL. Health care utilization by adult long-term survivors of hematopoietic cell transplant: Report from the bone marrow transplant survivor study. Cancer Epidemiology Biomarkers and Prevention 2007; 16(4):834-839.
|24. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303:1617-1624.
|25. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010.|
|Bone Marrow Transplant 2012; 47:906-923.
|26. Khera N, Storer B, Flowers M.E, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol 2012; 30:71-77.
|27. Inamoto Y, Shah NN, Savani B.N, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50:1013-1023
|28. Yoshimi A. Suzuki R. Atsuta Y. et al. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplant 2010; 45:1682-1691.
|29. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29(16):2230-2239.
|30. Atsuta Y, Hirakawa A, Nakasone H, et al; Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22(9):1702-1709.
|31. Francisco L, Armenian SH, Arora M, et al. Progressive decline in late mortality after hematopoietic cell transplantation (HCT) over 40 years-a report from BMTSS [abstract]. Blood 2016; 128(22):691.
|32. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28(6):1011-1016.
|33. Majhail NS, Bajorunaite R, Lazarus HM, et al. High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR. Bone Marrow Transplant 2011; 46:385-392.
Yousif NG, Alamran FG. System dynamics analysis of mortality post allogeneic hematopoietic stem cell transplant. American Journal of BioMedicine 2023; 11(3):110-123.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.